Show simple item record

dc.contributor.authorBrown, Marc
dc.contributor.authorEvans, Charles
dc.contributor.authorMuddle, Andrew
dc.contributor.authorTurner, Rob
dc.contributor.authorLim, Sian
dc.contributor.authorReid, Jessica
dc.contributor.authorTraynor, M.J.
dc.date.accessioned2013-09-26T12:30:09Z
dc.date.available2013-09-26T12:30:09Z
dc.date.issued2013-10
dc.identifier.citationBrown , M , Evans , C , Muddle , A , Turner , R , Lim , S , Reid , J & Traynor , M J 2013 , ' Efficacy, tolerability and consumer acceptability of terbinafine topical spray versus terbinafine topical solution : a phase IIa randomised, observer-blind, comparative study ' , American Journal of Clinical Dermatology , vol. 14 , no. 5 , pp. 413-419 . https://doi.org/10.1007/s40257-013-0031-y
dc.identifier.issn1179-1888
dc.identifier.otherPURE: 738079
dc.identifier.otherPURE UUID: 715e31c8-0c6a-4136-b977-eeb18b98525a
dc.identifier.otherScopus: 84885100939
dc.identifier.otherORCID: /0000-0001-7332-0011/work/32634796
dc.identifier.urihttp://hdl.handle.net/2299/11669
dc.description.abstractTinea pedis is one of the world's most prevalent dermatophyte infections. MedSprayTM tinea pedis 1 % w/w (topical spray) is a novel, easy to use propellant based spray formulation containing 1% w/w terbinafine, requiring no manipulation at the site of infection. This is in contrast to the only formulation currently approved in Europe for single application (non are approved in the US for single use) which is Lamisil® Once 1 % w/w (topical solution), containing 1% w/w terbinafine hydrochloride which requires manipulation on the affected area. The aim of this phase IIa randomised, observer-blind, comparative study was to evaluate the efficacy, tolerability and consumer acceptability of a topical spray versus a topical solution in the treatment of tinea pedis.en
dc.language.isoeng
dc.relation.ispartofAmerican Journal of Clinical Dermatology
dc.subjectAthletes foot
dc.subjectclinical trial
dc.subjecttinea pedis
dc.subjectterbinafine
dc.titleEfficacy, tolerability and consumer acceptability of terbinafine topical spray versus terbinafine topical solution : a phase IIa randomised, observer-blind, comparative studyen
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionPharmaceutics
dc.contributor.institutionSkin and Nail Group
dc.contributor.institutionAirway Group
dc.contributor.institutionBioadhesive Drug Delivery Group
dc.contributor.institutionNanopharmaceutics
dc.contributor.institutionPharmaceutical Analysis and Product Characterisation
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionToxicology
dc.description.statusPeer reviewed
rioxxterms.versionSMUR
rioxxterms.versionofrecordhttps://doi.org/10.1007/s40257-013-0031-y
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record